Clinical Trial

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Study acronym: AmyClearAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-16; most recent amendment 2025-07-01.
Trial Details
NCT Number NCT05059158
Lead Sponsor Ludwig-Maximilians - University of Munich
Conditions Alzheimer's Disease (AD)
Enrollment 60 participants
Start Date 2021-06-01
Primary Completion 2025-09 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-04